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You mentioned several different strategies to mainstream genetic screening for ovarian cancer with the most accepted being testing at time of diagnosis. What strategy would you like to see adopted?
We would like to see mainstream Response from Menon, Karpinskyj, and Gentry-Maharaj:
Question 2:
As the number of women having genetic testing increases, along with the ever-evolving information regarding genetic testing, it can be difficult to stay up to date on recommendations. What is the role of the general gynecologist in counseling women on screening and prevention? Should all at-risk women all be referred to a cancer management center?
At this point it is essential that general gynecologists are able to provide patients with an overview of risk factors, genetic testing, and available preventative/screening approaches. Most importantly, they should be aware of the national and local guidelines for referral to a family cancer and clinical genetics service and should identify a local clinic where they could refer unaffected patients who are at risk (currently this is largely based on family history). In unaffected women, confirmation of risk, counseling, genetic testing, and finalization of a tailored risk management plan is best carried out in the specialized multidisciplinary clinic. In some situations, the general gynecologist (as opposed to a gynecologic oncologist) may wish to work along with the family cancer multidisciplinary team to implement the agreed risk management (prevention and screening) plan in their high-risk patients. In the latter case, it is important that there is good communication between both teams so that any updates to recommendations are passed on to both the gynecologist and the patient. Question 3:
With increasing use of long-acting reversible contraceptives (LARC) by young women, do you feel there is a role for an oral contraceptive pill (OCP) in addition to LARC purely for chemoprophylaxis? Would you only recommend this in the high-risk population?
In Response from Menon, Karpinskyj, and Gentry-Maharaj:
Question 5:
Ovarian conservation does have known health benefits. Is there a risk group that you feel might benefit from risk-reducing salpingectomy alone without delayed oophorectomy? Would there be a role for this in women at low or moderate risk?
In young women at high risk, there is a definite role and the potential benefits and harms are being assessed in the context of multiple studies. In women at low risk, it is important to explore and discuss risk-reducing salpingectomy during intra-abdominal procedures where this might be safely carried out. However, presently there is no evidence to suggest that primary risk-reducing salpingectomy in patients at low or moderate risk is cost-effective.
Question 6:
Most of the research on screening has been done in either high-risk women or the general population. What are your screening recommendations for women at low or moderate risk for development of ovarian cancer? Response from Menon, Karpinskyj, and Gentry-Maharaj:
